Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 13/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5890712 | 0.92 | AVPR2 (0.48) | AVPR2AVPR1AROCK2ROCK1TP53 | |
| SCHEMBL6632264 | 0.91 | AVPR2 (0.52) | AVPR2AVPR1AROCK2ROCK1CYP11B1 | |
| SCHEMBL5891012 | 0.90 | AVPR2 (0.51) | AVPR2AVPR1AROCK2 | |
| SCHEMBL5890931 | 0.90 | AVPR2 (0.45) | AVPR2AVPR1AROCK2ROCK1TP53 | |
| SCHEMBL5890901 | 0.89 | AVPR2 (0.49) | AVPR2AVPR1A | |
| SCHEMBL5785287 | 0.88 | AVPR1A (0.55) | AVPR2AVPR1A | |
| SCHEMBL5890756 | 0.87 | AVPR2 (0.45) | AVPR2AVPR1AROCK2ROCK1CYP11B1 | |
| SCHEMBL5783851 | 0.87 | AVPR1A (0.54) | AVPR2AVPR1A | |
| SCHEMBL5890845 | 0.87 | AVPR2 (0.46) | AVPR2AVPR1AROCK2ROCK1TP53 | |
| SCHEMBL5891434 | 0.86 | AVPR2 (0.49) | AVPR2AVPR1AROCK2ROCK1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064120-B2 | Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-06-20 | — | — | US | claimed |
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | claimed |
| US-7064120-B2 | Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-06-20 | — | — | US | disclosed |
| WO-2002083683-A9 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | OXTR, OPRL1, OPRK1 | AVPR2 70/4885AVPR1A 33/4885ROCK2 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.